UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
1. GSK plans to invest $30 billion in U.S. R&D and manufacturing. 2. Investment includes $1.2 billion in advanced manufacturing and AI technologies. 3. GSK's commitment strengthens its existing U.S. R&D and supply chain. 4. CEO Emma Walmsley highlights the importance of U.S.-U.K. healthcare innovation collaboration. 5. Investment reflects GSK's long-term strategy in biopharma advancements.